title: Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.
abstract: BACKGROUND
  Treatment options for patients with metastatic uterine leiomyosarcoma are limited. Over the last few years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. The aim of this retrospective analysis was to look at the efficacy of trabectedin in the subgroup of uterine leiomyosarcoma.
  
  
  METHODS
  A retrospective analysis was carried out on patients with uterine leiomyosarcoma treated with trabectedin at two reference sarcoma centers between 2000 and 2010. Radiological response, progression-free and overall survival, as well as serious and unexpected adverse events, were assessed.
  
  
  RESULTS
  Sixty-six patients with metastatic uterine leiomyosarcoma were identified. The median number of previous chemotherapy regimens was 3 (range 1-5). Eleven patients (16%) achieved a partial response and 23 (35%) had a stable disease. The progression-free survival of the entire cohort was 3.3 months (CI 95% 2-5), and the progression-free rate at 3 and 6 months was 53% and 33%, respectively.
  
  
  CONCLUSIONS
  Trabectedin is a therapeutic option in the palliative approach to the metastatic uterine leiomyosarcoma patient.
authors.affiliation: Cancer Medicine Department, Adult Sarcoma Medical Oncology Unit, Istituto Nazionale Tumori, Milan, Italy. roberta.sanfilippo@istitutotumori.mi.it
authors.forename: Roberta
authors.initials: R
authors.lastname: Sanfilippo
authors.forename: Federica
authors.initials: F
authors.lastname: Grosso
authors.forename: Robin L
authors.initials: RL
authors.lastname: Jones
authors.forename: Susana
authors.initials: S
authors.lastname: Banerjee
authors.forename: Silvana
authors.initials: S
authors.lastname: Pilotti
authors.forename: Maurizio
authors.initials: M
authors.lastname: D'Incalci
authors.forename: Angelo Paolo
authors.initials: AP
authors.lastname: Dei Tos
authors.forename: Francesco
authors.initials: F
authors.lastname: Raspagliesi
authors.forename: Ian
authors.initials: I
authors.lastname: Judson
authors.forename: Paolo Giovanni
authors.initials: PG
authors.lastname: Casali
mesh_terms: D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004149:Dioxoles / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy* / Q000601:surgery; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D044005:Tetrahydroisoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D000077606:Trabectedin; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000601:surgery
chemical_list: D018906:Antineoplastic Agents, Alkylating; D004149:Dioxoles; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin